Patients and Partnerships

Recruiting patients to increase diversity & inclusion in clinical trials: one size does not fit all

More so now than ever, the inclusion of more diverse, and often more relevant, study populations is gathering momentum within the clinical trial community. From calls for more diversity in age, gender, and ethnic groups, to more consideration for lifestyle and cultural differences, trials need to ensure they represent the key population of interest and …

Recruiting patients to increase diversity & inclusion in clinical trials: one size does not fit all Read More »

The booming life sciences sector needs dynamic real estate support

Bruntwood SciTech is the UK’s leading property provider dedicated to driving the growth of the science and technology sector. UK life sciences are buoyant with the success of the COVID-19 vaccine programme and a stream of innovation and investment marking it out for a starring role in the UK’s economic future. The government has pledged …

The booming life sciences sector needs dynamic real estate support Read More »

How biomarkers and bioanalytics are changing R&D

Biomarkers have been causing a paradigm shift in how HCPs treat patients for some time – now they are bringing the pharma industry a new gold standard for clinical research. Thomas Turi, chief scientific officer at Nexelis, tells us how a biomarker-led R&D approach is transforming drug development in disease areas like non-alcoholic steatohepatitis (NASH) …

How biomarkers and bioanalytics are changing R&D Read More »

Health literacy for the intellectually disabled: is pharma doing enough?

What is health literacy and why is it important? Health literacy (HL), defined by the CDC as the degree to which individuals have the ability to find, understand and use information and services to inform health-related decisions and actions for themselves and others, is a valuable tool against health inequalities and negative patient outcomes. Low …

Health literacy for the intellectually disabled: is pharma doing enough? Read More »

Leveraging real-world data to meet payers’ needs

Payers are becoming savvier in accepting real-world data. Certara’s Lee Stern and Shawn Bates discuss the challenges and how pharma can use real-world data to meet payers’ needs. For years, clinical trial data was king. But as healthcare costs continue to be squeezed, there is pressure on pharmaceutical companies to actually deliver on clinical trial …

Leveraging real-world data to meet payers’ needs Read More »

Time for a new model in patient access

Mig Sleeper, vice president, Global Pricing for Astellas Pharma Europe, explains why we must rethink how value is defined as we enter a new technological era for medicines.   Why is a new access model so pressing, and has the pandemic accelerated the situation? Yes, it has. Although the need for a change in the …

Time for a new model in patient access Read More »

Time to take patient engagement to the next level

Patient engagement in pharma is evolving, with some companies doing it better than others. Envision Pharma Group’s Dawn Lobban and Sarah Avent discuss the need to engage with patients at every level for holistic inclusion of the patient voice in order for pharma to become truly patient-centric. The Covid pandemic has sparked people’s interest in …

Time to take patient engagement to the next level Read More »

Patients want to be heard. Is pharma listening?

A common theme heard from the advocacy groups AXON works with is “Nothing for us without us,” says Natalie Turner, director at AXON, a global healthcare communications agency. Patients want to be part of the healthcare conversation and genuinely heard by those who make the final decisions, but pharma does not always understand how to …

Patients want to be heard. Is pharma listening? Read More »

Three views on technology improving clinical trial efficiency

Marie Emms, vice president of site and patient participation at Syneos Health, tells us technology helped increase patient enrolment, improve diversity and inclusion, and boost retention rates for clinical trials after the pandemic. Still, she says a lot needs to be done to continue this upward trajectory. “There’s an acknowledgement among companies that the paradigm …

Three views on technology improving clinical trial efficiency Read More »

Emerging from the shadow of COVID-19

We now have a unique opportunity to re-discover what matters most to patients, says Alnylam’s Kasha Witkos. In the biotech industry, if you are not motivated by helping patients and potentially transforming their lives, then you’re in the wrong job. Yet understanding what people go through on their journey – particularly those living with a …

Emerging from the shadow of COVID-19 Read More »